CN116173238A - 用于检测和治疗阿尔茨海默病的组合物及方法 - Google Patents

用于检测和治疗阿尔茨海默病的组合物及方法 Download PDF

Info

Publication number
CN116173238A
CN116173238A CN202310211448.7A CN202310211448A CN116173238A CN 116173238 A CN116173238 A CN 116173238A CN 202310211448 A CN202310211448 A CN 202310211448A CN 116173238 A CN116173238 A CN 116173238A
Authority
CN
China
Prior art keywords
ligand
nanometer
amyloid
ligands
droplet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310211448.7A
Other languages
English (en)
Chinese (zh)
Inventor
埃文·C·昂格尔
伊曼·达叶瑞
伊曼纽尔·乔尔·梅勒特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microvascular Therapeutics LLC
Original Assignee
Microvascular Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microvascular Therapeutics LLC filed Critical Microvascular Therapeutics LLC
Publication of CN116173238A publication Critical patent/CN116173238A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasonic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
CN202310211448.7A 2018-03-29 2019-03-28 用于检测和治疗阿尔茨海默病的组合物及方法 Pending CN116173238A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862650239P 2018-03-29 2018-03-29
US62/650,239 2018-03-29
PCT/US2019/024713 WO2019191518A1 (en) 2018-03-29 2019-03-28 Compositions and methods of detecting and treating alzheimer's disease
CN201980035749.0A CN112384202B (zh) 2018-03-29 2019-03-28 用于检测和治疗阿尔茨海默病的组合物及方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980035749.0A Division CN112384202B (zh) 2018-03-29 2019-03-28 用于检测和治疗阿尔茨海默病的组合物及方法

Publications (1)

Publication Number Publication Date
CN116173238A true CN116173238A (zh) 2023-05-30

Family

ID=68060802

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310211448.7A Pending CN116173238A (zh) 2018-03-29 2019-03-28 用于检测和治疗阿尔茨海默病的组合物及方法
CN201980035749.0A Active CN112384202B (zh) 2018-03-29 2019-03-28 用于检测和治疗阿尔茨海默病的组合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980035749.0A Active CN112384202B (zh) 2018-03-29 2019-03-28 用于检测和治疗阿尔茨海默病的组合物及方法

Country Status (8)

Country Link
US (1) US20210008204A1 (https=)
EP (1) EP3773500A4 (https=)
JP (2) JP2021519324A (https=)
KR (1) KR20210018789A (https=)
CN (2) CN116173238A (https=)
AU (2) AU2019243579B2 (https=)
CA (1) CA3094377A1 (https=)
WO (1) WO2019191518A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
EP3773500A4 (en) * 2018-03-29 2022-03-16 Microvascular Therapeutics LLC COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
KR102490837B1 (ko) * 2020-03-19 2023-01-19 포항공과대학교 산학협력단 뇌-혈관 장벽 투과성을 증가시키는 방법
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028066A (en) * 1997-05-06 2000-02-22 Imarx Pharmaceutical Corp. Prodrugs comprising fluorinated amphiphiles
US6264917B1 (en) * 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
US20140004172A1 (en) * 2012-06-28 2014-01-02 Massimo Masserini Liposomes active in-vivo on neurodegenerative diseases
CN107106708A (zh) * 2014-10-08 2017-08-29 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像
CN107106692A (zh) * 2014-06-12 2017-08-29 埃文·C·昂格尔 磷脂组合物和微囊及使用磷脂组合物和微囊形成的乳剂
CN112384202A (zh) * 2018-03-29 2021-02-19 微脉管治疗有限公司 用于检测和治疗阿尔茨海默病的组合物及方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264917B1 (en) * 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
US6028066A (en) * 1997-05-06 2000-02-22 Imarx Pharmaceutical Corp. Prodrugs comprising fluorinated amphiphiles
US20140004172A1 (en) * 2012-06-28 2014-01-02 Massimo Masserini Liposomes active in-vivo on neurodegenerative diseases
CN107106692A (zh) * 2014-06-12 2017-08-29 埃文·C·昂格尔 磷脂组合物和微囊及使用磷脂组合物和微囊形成的乳剂
CN107106708A (zh) * 2014-10-08 2017-08-29 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像
CN112384202A (zh) * 2018-03-29 2021-02-19 微脉管治疗有限公司 用于检测和治疗阿尔茨海默病的组合物及方法
CN112384202B (zh) * 2018-03-29 2023-03-21 微脉管治疗有限公司 用于检测和治疗阿尔茨海默病的组合物及方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CLAUDIA BALDUCCI等: "Multifunctional Liposomes Reduce Brain β-Amyloid Burden and Ameliorate Memory Impairment in Alzheimer\'s Disease Mouse Models", JOURNAL OF NEUROSCIENCE, vol. 34, no. 42, 15 October 2014 (2014-10-15), pages 14022 - 14031, XP055676978, DOI: 10.1523/JNEUROSCI.0284-14.2014 *
EVAN C. UNGER等: "Therapeutic applications of lipid-coated microbubbles", ADVANCED DRUG DELIVERY REVIEWS, vol. 56, no. 9, 7 May 2004 (2004-05-07), pages 1291 - 1314, XP002468886, DOI: 10.1016/j.addr.2003.12.006 *
GERHARD LEINENGA等: "Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 278, 11 March 2015 (2015-03-11), pages 278, XP055509497 *
LOCKHART A: "Imaging Alzheimer\'s disease pathology: one target, many ligands", DRUG DISCOVERY TODAY, vol. 11, no. 23, 31 December 2006 (2006-12-31), pages 1093 - 1099 *
PHILIP B. VERGHESE等: "ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions", PNAS, 24 April 2013 (2013-04-24), pages 1807 *
TANIFUM E A等: "Intravenous delivery of targeted liposomes to amyloid-β pathology in APP/PSEN1 transgenic mice", PLOS ONE, vol. 7, no. 10, 31 October 2012 (2012-10-31), pages 48515 *
TANIFUM, E. A.等: "A novel liposomal nanoparticle for the imaging of amyloid plaque by magnetic resonance imaging", JOURNAL OF ALZHEIMER\'S DISEASE, vol. 52, no. 2, 4 July 2016 (2016-07-04), pages 731 - 745, XP055477335, DOI: 10.3233/JAD-151124 *
THANH DUC MAI等: "Single-step immunoassays and microfluidic droplet operation: Towards a versatile approach for detection of amyloid-peptide-based biomarkers of Alzheimer’s disease", vol. 255, 5 September 2017 (2017-09-05), pages 2126 - 2135 *

Also Published As

Publication number Publication date
KR20210018789A (ko) 2021-02-18
CN112384202B (zh) 2023-03-21
US20210008204A1 (en) 2021-01-14
CN112384202A (zh) 2021-02-19
AU2019243579A1 (en) 2020-10-22
AU2024205163A1 (en) 2024-08-15
JP2025000828A (ja) 2025-01-07
CA3094377A1 (en) 2019-10-03
AU2019243579B2 (en) 2024-05-09
EP3773500A1 (en) 2021-02-17
JP2021519324A (ja) 2021-08-10
EP3773500A4 (en) 2022-03-16
WO2019191518A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
CN112384202B (zh) 用于检测和治疗阿尔茨海默病的组合物及方法
JP5513708B2 (ja) 造影イメージング用の気体封入マイクロベシクル・アセンブリー
CN1102045C (zh) 新的含类脂和稳定剂的组合物
CA2649207C (en) Magnetic nanoparticles compositions and uses thereof
CN1897978B (zh) 具有用于反差成像的活性组分的充气微囊组件
AU2002213285B2 (en) Novel targeted compositions for diagnostic and therapeutic use
JP5420410B2 (ja) ポリマー修飾脂質を含むガス封入微小胞
Brambila et al. Bubble inflation using phase-change perfluorocarbon nanodroplets as a strategy for enhanced ultrasound imaging and therapy
Weldon et al. Nanoscale bupivacaine formulations to enhance the duration and safety of intravenous regional anesthesia
Fatfat et al. Nanoliposomes as safe and efficient drug delivery nanovesicles
US20110059020A1 (en) Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same
US20240148914A1 (en) Compositions and methods of detecting and treating thrombosis and vascular plaques
JP2020516686A (ja) 活性化ｃｄ４４分子を標的とするセラソーム送達システム、その調製方法および使用
Vichare et al. Perfluorocarbon nanoemulsions in drug delivery: design, development, and manufacturing
US10010630B2 (en) Gas-filled microvesicles
US20110104258A1 (en) Technique for drug and gene delivery to the cell cytosol
US20220023447A1 (en) Fibrin-targeted polymerized shell lipid microbubbles for diagnostic and therapeutic applications
JP5463548B2 (ja) 超音波治療用リポソーム及び超音波治療促進用リポソーム
JP2018197208A (ja) 一酸化窒素内包バブルリポソーム及びその利用
Pitt et al. Technique for drug and gene delivery to the cell cytosol
Sekaringtyas Assessment of Lipid Nanocapsules and Liposomes as Nanocarriers for C6 Ceramide Delivery to Breast Cancer Cells
Shi Ultrasound activated drug release with hydrogen bonded frameworks and extracellular vesicles
Ranjan Liposome nanoparticles for targeted drug delivery, gene delivery and magnetic imaging
EP2545908A1 (en) Medium for microbubbles or microparticles and preparation thereof
Lukáč Micro and Nanoparticles as Drug Carriers: Surface-Modified Microbubbles Used as Ultrasound Contrast Agents and Drug Carriers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination